KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Other Accumulated Expenses (2018 - 2025)

Historic Other Accumulated Expenses for Bristol Myers Squibb (BMY) over the last 15 years, with Q3 2025 value amounting to $19.3 billion.

  • Bristol Myers Squibb's Other Accumulated Expenses rose 689.85% to $19.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $19.3 billion, marking a year-over-year increase of 689.85%. This contributed to the annual value of $18.1 billion for FY2024, which is 1411.48% up from last year.
  • Bristol Myers Squibb's Other Accumulated Expenses amounted to $19.3 billion in Q3 2025, which was up 689.85% from $17.4 billion recorded in Q2 2025.
  • In the past 5 years, Bristol Myers Squibb's Other Accumulated Expenses registered a high of $19.3 billion during Q3 2025, and its lowest value of $12.4 billion during Q1 2022.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $14.6 billion (2022), whereas its average is $15.1 billion.
  • In the last 5 years, Bristol Myers Squibb's Other Accumulated Expenses tumbled by 1919.37% in 2021 and then surged by 2248.27% in 2024.
  • Quarter analysis of 5 years shows Bristol Myers Squibb's Other Accumulated Expenses stood at $14.0 billion in 2021, then rose by 4.4% to $14.6 billion in 2022, then rose by 8.9% to $15.9 billion in 2023, then grew by 14.11% to $18.1 billion in 2024, then increased by 6.69% to $19.3 billion in 2025.
  • Its Other Accumulated Expenses was $19.3 billion in Q3 2025, compared to $17.4 billion in Q2 2025 and $16.5 billion in Q1 2025.